Wen-KaiWengMD

Oncology • Stanford, CA

Hematologic Oncology

Associate Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to view full profile

Dr. Weng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weng's full profile

Already have an account?

Office
300 Pasteur Dr
# MC5623
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1999 - 2004
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1996 - 1999
Chung Shan Medical UniversityClass of 1988

Certifications & Licensure

CA State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma Start of enrollment: 2000 Aug 01
Completed
Phase 2
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma Start of enrollment: 2000 Apr 01
Completed
Phase 2
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Start of enrollment: 2000 Nov 01
Completed
Not Applicable
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Start of enrollment: 2009 May 01
Completed
Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Start of enrollment: 2011 May 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Efficacy of Hedgehog Pathway Inhibitors as Adjuvant in Treating Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease.
Andres Mendez-Hernandez, Ridhi Gupta, Sally Arai, Robert Lowsky, Bernice Kwong
Journal of the American Academy of Dermatology. 2025-01-21
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Everett Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron S Bader, Bryan Xie
Blood. 2025-01-10
1 citations
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBAL...
Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain
The Lancet. Oncology. 2025-01-01

Abstracts/Posters

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Wen-Kai Weng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
Wen-Kai Weng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021